<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>BioScreening.net &#187; Drug-Like Compounds</title>
	<atom:link href="http://www.bioscreening.net/category/news/drug-like-compounds/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.bioscreening.net</link>
	<description>BioScreening news and events</description>
	<lastBuildDate>Thu, 29 Dec 2011 08:21:20 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3</generator>
		<item>
		<title>Natural compounds derived from plants could yield hundreds of new drugs</title>
		<link>http://www.bioscreening.net/2011/12/22/natural-compounds-derived-from-plants-could-yield-hundreds-of-new-drugs/</link>
		<comments>http://www.bioscreening.net/2011/12/22/natural-compounds-derived-from-plants-could-yield-hundreds-of-new-drugs/#comments</comments>
		<pubDate>Thu, 22 Dec 2011 08:10:33 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Compound Libraries]]></category>
		<category><![CDATA[Drug-Like Compounds]]></category>
		<category><![CDATA[Natural Products]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1367</guid>
		<description><![CDATA[NYBG scientist says the plant world has &#8220;great potential&#8221; as a source of new medicines There are probably at least 500 medically useful chemicals awaiting discovery in plant species whose chemical constituents have not yet been evaluated for their potential to cure or treat disease, according to a new analysis by a New York Botanical [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/12/22/natural-compounds-derived-from-plants-could-yield-hundreds-of-new-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>BioFocus to Offer IMD’s Natural Product Libraries through Drug Discovery Services</title>
		<link>http://www.bioscreening.net/2011/08/02/biofocus-to-offer-imd%e2%80%99s-natural-product-libraries-through-drug-discovery-services/</link>
		<comments>http://www.bioscreening.net/2011/08/02/biofocus-to-offer-imd%e2%80%99s-natural-product-libraries-through-drug-discovery-services/#comments</comments>
		<pubDate>Tue, 02 Aug 2011 16:44:07 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[BioInformatics]]></category>
		<category><![CDATA[Diversity Libraries]]></category>
		<category><![CDATA[Drug-Like Compounds]]></category>
		<category><![CDATA[Natural Products]]></category>
		<category><![CDATA[Targeted Libraries]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1227</guid>
		<description><![CDATA[BioFocus and InterMed Discovery (IMD) inked a marketing collaboration that will allow BioFocus to offer IMD’s natural product screening libraries through its drug discovery services. IMD will in addition provide follow-on services to BioFocus. “We have been impressed with the scale of IMD’s natural product discovery capabilities, and we believe that when InterMed’s natural product [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/08/02/biofocus-to-offer-imd%e2%80%99s-natural-product-libraries-through-drug-discovery-services/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TimTec Launches Division of Organic Synthesis and Medicinal Chemistry Contract Research Services</title>
		<link>http://www.bioscreening.net/2010/07/08/timtec-launches-division-of-organic-synthesis-and-medicinal-chemistry-contract-research-services/</link>
		<comments>http://www.bioscreening.net/2010/07/08/timtec-launches-division-of-organic-synthesis-and-medicinal-chemistry-contract-research-services/#comments</comments>
		<pubDate>Fri, 09 Jul 2010 03:39:07 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[ADMET Studies]]></category>
		<category><![CDATA[Business and Investment]]></category>
		<category><![CDATA[Drug-Like Compounds]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Research Projects]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/07/08/timtec-launches-division-of-organic-synthesis-and-medicinal-chemistry-contract-research-services/</guid>
		<description><![CDATA[Newark, DE, July 8, 2010 Press Release &#8211; TimTec, LLC is pleased to announce the launching of the new Division that manages Organic Synthesis and Medicinal Chemistry Contract Research Services. The emergence of the division is an evolutionarily progression for TimTecs business development. The company has been known for its expertise in organic chemistry design [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/07/08/timtec-launches-division-of-organic-synthesis-and-medicinal-chemistry-contract-research-services/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TimTec&#8217;s Contract Research Services</title>
		<link>http://www.bioscreening.net/2010/07/08/contract-research-services/</link>
		<comments>http://www.bioscreening.net/2010/07/08/contract-research-services/#comments</comments>
		<pubDate>Thu, 08 Jul 2010 19:22:09 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[ADMET Studies]]></category>
		<category><![CDATA[Drug-Like Compounds]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Research Projects]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/07/08/contract-research-services/</guid>
		<description><![CDATA[High Quality Organic Synthesis and Medicinal Chemistry Contract Research Services at an Outstanding Value TimTec brings 15 years of expertise in organic chemistry design and supply for drug discovery closer to your supplemental bench-top requirements by launching The Organic Synthesis and Medicinal Chemistry Contract Research Services Division. TimTec scientists have a proven track record of [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/07/08/contract-research-services/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening</title>
		<link>http://www.bioscreening.net/2010/05/05/cellular-dynamics-announces-commercial-launch-of-icelltm-cardiomyocytes-for-drug-candidate-toxicity-screening/</link>
		<comments>http://www.bioscreening.net/2010/05/05/cellular-dynamics-announces-commercial-launch-of-icelltm-cardiomyocytes-for-drug-candidate-toxicity-screening/#comments</comments>
		<pubDate>Wed, 05 May 2010 14:36:09 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Drug-Like Compounds]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/05/05/cellular-dynamics-announces-commercial-launch-of-icelltm-cardiomyocytes-for-drug-candidate-toxicity-screening/</guid>
		<description><![CDATA[Human iCell Cardiomyocytes Provide Alternative to Non-human, Tumor-derived, and Cadaveric Cellular Model Systems to Better Predict Cardiac Toxicity MADISON, Wis., Dec. 16 /PRNewswire/ &#8212; Cellular Dynamics International (CDI) today announced the commercial launch of iCell(TM) Cardiomyocytes for use in testing of new drug candidates by the pharmaceutical industry. These human heart cells are designed to [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/05/05/cellular-dynamics-announces-commercial-launch-of-icelltm-cardiomyocytes-for-drug-candidate-toxicity-screening/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Alzheimer&#8217;s Research Provides Potential Treatment for UTI</title>
		<link>http://www.bioscreening.net/2010/01/11/alzheimers-research-provides-potential-treatment-for-uti/</link>
		<comments>http://www.bioscreening.net/2010/01/11/alzheimers-research-provides-potential-treatment-for-uti/#comments</comments>
		<pubDate>Mon, 11 Jan 2010 22:05:50 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Drug-Like Compounds]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/01/11/alzheimers-research-provides-potential-treatment-for-uti/</guid>
		<description><![CDATA[One element links the disparate areas of research: amyloids, which are fibrous, sticky protein aggregates. Some infectious bacteria use amyloids to attach to host cells and to build biofilms, which are bacterial communities bound together in a film that helps resist antibiotics and immune attacks. Amyloids also form in the nervous system in Alzheimer&#8217;s disease, [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/01/11/alzheimers-research-provides-potential-treatment-for-uti/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Families of Spinal Muscular Atrophy Funded Program Shows Quinazoline Compounds Give Survival Benefit in a Severe Mouse Model of SMA.</title>
		<link>http://www.bioscreening.net/2009/12/28/families-of-spinal-muscular-atrophy-funded-program-shows-quinazoline-compounds-give-survival-benefit-in-a-severe-mouse-model-of-sma/</link>
		<comments>http://www.bioscreening.net/2009/12/28/families-of-spinal-muscular-atrophy-funded-program-shows-quinazoline-compounds-give-survival-benefit-in-a-severe-mouse-model-of-sma/#comments</comments>
		<pubDate>Mon, 28 Dec 2009 16:06:54 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[Drug-Like Compounds]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/12/28/families-of-spinal-muscular-atrophy-funded-program-shows-quinazoline-compounds-give-survival-benefit-in-a-severe-mouse-model-of-sma/</guid>
		<description><![CDATA[This publication, showing data from the testing of Quinazoline derivatives in a Spinal Muscular Atrophy mouse model, has been published in Human Molecular Genetics by lead author Dr. Matthew Butchbach from the laboratory of Dr. Arthur Burghes at the Ohio State University. The generation of theÂ Quinazoline compounds as a therapeutic drug candidate for Spinal Muscular [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/12/28/families-of-spinal-muscular-atrophy-funded-program-shows-quinazoline-compounds-give-survival-benefit-in-a-severe-mouse-model-of-sma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Tapeworm Drug May Hold Promise For Colon Cancer, Future Research</title>
		<link>http://www.bioscreening.net/2009/12/15/tapeworm-drug-may-hold-promise-for-colon-cancer-future-research/</link>
		<comments>http://www.bioscreening.net/2009/12/15/tapeworm-drug-may-hold-promise-for-colon-cancer-future-research/#comments</comments>
		<pubDate>Tue, 15 Dec 2009 19:22:38 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Drug-Like Compounds]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/12/15/tapeworm-drug-may-hold-promise-for-colon-cancer-future-research/</guid>
		<description><![CDATA[The findings about this compound, published in the Nov. 3 issue of Biochemistry journal, might prove valuable to patients and clinicians, who may benefit if there is a demonstrated boost to chemotherapy. Researchers also can use the compound to manipulate the receptor to learn more about a common cell replenishing pathway, called the Wnt pathway, [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/12/15/tapeworm-drug-may-hold-promise-for-colon-cancer-future-research/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sirona Biochem Says SGLT Test Results Confirm Key &#8216;Breakthrough&#8217;</title>
		<link>http://www.bioscreening.net/2009/10/09/sirona-biochem-says-sglt-test-results-confirm-key-breakthrough/</link>
		<comments>http://www.bioscreening.net/2009/10/09/sirona-biochem-says-sglt-test-results-confirm-key-breakthrough/#comments</comments>
		<pubDate>Fri, 09 Oct 2009 16:02:51 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Cell Analysis]]></category>
		<category><![CDATA[Cell-based Assays]]></category>
		<category><![CDATA[Compound Libraries]]></category>
		<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Diversity Libraries]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Drug-Like Compounds]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/10/09/sirona-biochem-says-sglt-test-results-confirm-key-breakthrough/</guid>
		<description><![CDATA[Sirona Biochem Corp. (TSX-V: SBM), an emerging biotech company focused on diabetes and obesity, says results of testing its unique SGLT inhibitor molecules demonstrate a key breakthrough milestone for Sirona Biochem. Sirona Biochem CEO, Dr. Howard Verrico, said, &#8220;There are two vital steps in the early stage of drug testing: validation of concept i.e. a [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/10/09/sirona-biochem-says-sglt-test-results-confirm-key-breakthrough/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Agilux Laboratories Hires New Associate Director to Lead In Vitro ADMET Services Division</title>
		<link>http://www.bioscreening.net/2009/10/08/agilux-laboratories-hires-new-associate-director-to-lead-in-vitro-admet-services-division/</link>
		<comments>http://www.bioscreening.net/2009/10/08/agilux-laboratories-hires-new-associate-director-to-lead-in-vitro-admet-services-division/#comments</comments>
		<pubDate>Thu, 08 Oct 2009 16:22:06 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Compound Libraries]]></category>
		<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Drug-Like Compounds]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Reports]]></category>
		<category><![CDATA[Research Projects]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/10/08/agilux-laboratories-hires-new-associate-director-to-lead-in-vitro-admet-services-division/</guid>
		<description><![CDATA[- Adrian Sheldon, Ph.D., Positions Contract Research Organization for Growth - WORCESTER, Mass.--(Business Wire)-- Agilux Laboratories, Inc., a Contract Research Organization (CRO) that provides bioanalytical and in vitro Absorption Distribution Metabolism Excretion Toxicology (ADMET) services for the biotechnology and pharmaceutical industries, has appointed Dr. Adrian Sheldon as associate director of In Vitro ADMET Services. In [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/10/08/agilux-laboratories-hires-new-associate-director-to-lead-in-vitro-admet-services-division/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Evotec Announces Research Agreement With Biogen Idec</title>
		<link>http://www.bioscreening.net/2009/10/08/evotec-announces-research-agreement-with-biogen-idec/</link>
		<comments>http://www.bioscreening.net/2009/10/08/evotec-announces-research-agreement-with-biogen-idec/#comments</comments>
		<pubDate>Thu, 08 Oct 2009 16:14:35 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Business and Investment]]></category>
		<category><![CDATA[Collaborations]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Drug-Like Compounds]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Research Projects]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/10/08/evotec-announces-research-agreement-with-biogen-idec/</guid>
		<description><![CDATA[HAMBURG, Germany and OXFORD, UK, Sept. 9, 2009 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (Nasdaq:EVTC), a leading provider in the discovery and development of novel small molecule drugs, today announced that it has entered into a research agreement with Biogen Idec (Nasdaq:BIIB), a leading biopharmaceutical company headquartered in Cambridge, Mass., USA. Evotec will use its [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/10/08/evotec-announces-research-agreement-with-biogen-idec/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>KINAXO launches KinAffinityÂ® services for efficient profiling of kinase inhibitors in cells or tissue</title>
		<link>http://www.bioscreening.net/2009/10/08/kinaxo-launches-kinaffinity%c2%ae-services-for-efficient-profiling-of-kinase-inhibitors-in-cells-or-tissue/</link>
		<comments>http://www.bioscreening.net/2009/10/08/kinaxo-launches-kinaffinity%c2%ae-services-for-efficient-profiling-of-kinase-inhibitors-in-cells-or-tissue/#comments</comments>
		<pubDate>Thu, 08 Oct 2009 14:53:14 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Drug-Like Compounds]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/10/08/kinaxo-launches-kinaffinity%c2%ae-services-for-efficient-profiling-of-kinase-inhibitors-in-cells-or-tissue/</guid>
		<description><![CDATA[Martinsried, Germany, October 01, 2009 / b3c newswire / -Â  KINAXO Biotechnologies GmbH announced today that it added KinAffinityÂ® to its service portfolio. KinAffinityÂ® provides invaluable information about a kinase inhibitorâ€™s selectivity in a cell or tissue of interest. It simultaneously determines affinities for native kinases expressed within a cellular proteome and thus overcomes the [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/10/08/kinaxo-launches-kinaffinity%c2%ae-services-for-efficient-profiling-of-kinase-inhibitors-in-cells-or-tissue/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Plexxikon Receives Key Patents on Novel Compounds for Multiple Programs</title>
		<link>http://www.bioscreening.net/2009/03/27/plexxikon-receives-key-patents-on-novel-compounds-for-multiple-programs-2/</link>
		<comments>http://www.bioscreening.net/2009/03/27/plexxikon-receives-key-patents-on-novel-compounds-for-multiple-programs-2/#comments</comments>
		<pubDate>Sat, 28 Mar 2009 02:00:19 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[ChemInformatics]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Compound Libraries]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Drug-Like Compounds]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Targeted Libraries]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/03/27/plexxikon-receives-key-patents-on-novel-compounds-for-multiple-programs-2/</guid>
		<description><![CDATA[BERKELEY, Calif.&#8211;(BUSINESS WIRE)&#8211;Plexxikon Inc. today announced the issuance of key composition-of-matter patents covering novel compounds discovered through the companyâ€™s Scaffold-Based Drug Discoveryâ„¢ platform. Plexxikonâ€™s pipeline of preclinical and clinical stage product opportunities currently span potential treatments for cardio-renal disease, CNS disorders, inflammation, metabolic disease and oncology. Two of the three recently issued patents (U.S. patents [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/03/27/plexxikon-receives-key-patents-on-novel-compounds-for-multiple-programs-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Thermo Fisher Scientific Accelerates Drug Discovery Process With New Maybridge Quick2Leadâ„¢ Compound Kits</title>
		<link>http://www.bioscreening.net/2009/03/27/thermo-fisher-scientific-accelerates-drug-discovery-process-with-new-maybridge-quick2lead%e2%84%a2-compound-kits/</link>
		<comments>http://www.bioscreening.net/2009/03/27/thermo-fisher-scientific-accelerates-drug-discovery-process-with-new-maybridge-quick2lead%e2%84%a2-compound-kits/#comments</comments>
		<pubDate>Sat, 28 Mar 2009 01:32:03 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Compound Libraries]]></category>
		<category><![CDATA[Diversity Libraries]]></category>
		<category><![CDATA[Drug-Like Compounds]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/03/27/thermo-fisher-scientific-accelerates-drug-discovery-process-with-new-maybridge-quick2lead%e2%84%a2-compound-kits/</guid>
		<description><![CDATA[Thermo Fisher Scientific, the world leader in serving science, announced recently that it has introduced a novel tool to accelerate hit-to-lead programmes in the drug discovery process. Its Maybridge Quick2Leadâ„¢ Compound Kits are designed to save time and money by enabling rapid compound library synthesis around bioactive &#8220;hits&#8221; emerging from screening assays. The kits are [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/03/27/thermo-fisher-scientific-accelerates-drug-discovery-process-with-new-maybridge-quick2lead%e2%84%a2-compound-kits/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Plexxikon Receives Key Patents on Novel Compounds for Multiple Programs</title>
		<link>http://www.bioscreening.net/2009/03/20/plexxikon-receives-key-patents-on-novel-compounds-for-multiple-programs/</link>
		<comments>http://www.bioscreening.net/2009/03/20/plexxikon-receives-key-patents-on-novel-compounds-for-multiple-programs/#comments</comments>
		<pubDate>Fri, 20 Mar 2009 20:54:46 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Drug-Like Compounds]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Targeted Libraries]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/03/20/plexxikon-receives-key-patents-on-novel-compounds-for-multiple-programs/</guid>
		<description><![CDATA[BERKELEY, Calif.&#8211;(BUSINESS WIRE)&#8211;Plexxikon Inc. today announced the issuance of key composition-of-matter patents covering novel compounds discovered through the companyâ€™s Scaffold-Based Drug Discoveryâ„¢ platform. Plexxikonâ€™s pipeline of preclinical and clinical stage product opportunities currently span potential treatments for cardio-renal disease, CNS disorders, inflammation, metabolic disease and oncology. Two of the three recently issued patents (U.S. patents [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/03/20/plexxikon-receives-key-patents-on-novel-compounds-for-multiple-programs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>European Molecular Biology Laboratory (EMBL) Signs Agreement to License Themis and Surflex-Dock Technologies from Tripos</title>
		<link>http://www.bioscreening.net/2009/02/18/european-molecular-biology-laboratory-embl-signs-agreement-to-license-themis-and-surflex-dock-technologies-from-tripos/</link>
		<comments>http://www.bioscreening.net/2009/02/18/european-molecular-biology-laboratory-embl-signs-agreement-to-license-themis-and-surflex-dock-technologies-from-tripos/#comments</comments>
		<pubDate>Wed, 18 Feb 2009 20:13:56 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Business and Investment]]></category>
		<category><![CDATA[Collaborations]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Drug-Like Compounds]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Events]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/02/18/european-molecular-biology-laboratory-embl-signs-agreement-to-license-themis-and-surflex-dock-technologies-from-tripos/</guid>
		<description><![CDATA[ST. LOUIS, Mo.&#8211;(BUSINESS WIRE)&#8211;Triposâ„¢, a leading provider of drug discovery informatics products and services, today announced an agreement with the European Molecular Biology Laboratory (EMBL), Europeâ€™s leading research institution for molecular biology, to license Triposâ€™ Themisâ„¢ and Surflex-Dockâ„¢ software to support their efforts in Chemical Biology. According to Dr. Joe Lewis, Head of the Chemical [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/02/18/european-molecular-biology-laboratory-embl-signs-agreement-to-license-themis-and-surflex-dock-technologies-from-tripos/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ZINC Database &#8211; emolecule repository</title>
		<link>http://www.bioscreening.net/2009/01/12/zinc-database-emolecule-repository/</link>
		<comments>http://www.bioscreening.net/2009/01/12/zinc-database-emolecule-repository/#comments</comments>
		<pubDate>Mon, 12 Jan 2009 19:52:58 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[ChemInformatics]]></category>
		<category><![CDATA[Compound Libraries]]></category>
		<category><![CDATA[Drug-Like Compounds]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/01/12/zinc-database-emolecule-repository/</guid>
		<description><![CDATA[What is ZINC? It is a free database of millions of commercially-available compounds for virtual screening in ready-to-dock format. Why is it needed? Compounds that are available today can become unavailable in six months because of unavailability of the underlying reagents. For most vendors, the list of available compounds is significantly smaller than the list [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/01/12/zinc-database-emolecule-repository/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>IPR story 12- Patenting a mere idea</title>
		<link>http://www.bioscreening.net/2008/11/26/ipr-story-12-patenting-a-mere-idea/</link>
		<comments>http://www.bioscreening.net/2008/11/26/ipr-story-12-patenting-a-mere-idea/#comments</comments>
		<pubDate>Wed, 26 Nov 2008 18:14:55 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Biotech & Pharma Law]]></category>
		<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Drug-Like Compounds]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[News by Subject]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2008/11/26/ipr-story-12-patenting-a-mere-idea/</guid>
		<description><![CDATA[Jaidev had joined a leading Pharmaceutical Research Institute in India, for his Ph.D work. He reviewed his research plan thoroughly and also searched patents. Based on discussions with his guide, he formulated a very innovative research plan, pertaining to development of a new screening method for diabetic compounds. He started his work and after nearly [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2008/11/26/ipr-story-12-patenting-a-mere-idea/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Virtual Screening Gives Drug Design a Boost</title>
		<link>http://www.bioscreening.net/2008/11/19/virtual-screening-gives-drug-design-a-boost/</link>
		<comments>http://www.bioscreening.net/2008/11/19/virtual-screening-gives-drug-design-a-boost/#comments</comments>
		<pubDate>Wed, 19 Nov 2008 21:07:46 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[BioInformatics]]></category>
		<category><![CDATA[ChemInformatics]]></category>
		<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[Drug-Like Compounds]]></category>
		<category><![CDATA[HIV Research]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Targeted Libraries]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2008/11/19/virtual-screening-gives-drug-design-a-boost/</guid>
		<description><![CDATA[San Diego, CA (OBBeC) â€“ Researchers at the University of California, San Diego, developed a unique computational approach to identify key compounds that could lead to new drugs to combat African sleeping sickness &#8212; a disease spread by the biting tsetse fly and caused by the parasite Trypanosoma brucei. Around 150,000 people per year get [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2008/11/19/virtual-screening-gives-drug-design-a-boost/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>WuXi PharmaTech Inks New Three-year Deal with Pfizer</title>
		<link>http://www.bioscreening.net/2008/11/11/wuxi-pharmatech-inks-new-three-year-deal-with-pfizer/</link>
		<comments>http://www.bioscreening.net/2008/11/11/wuxi-pharmatech-inks-new-three-year-deal-with-pfizer/#comments</comments>
		<pubDate>Tue, 11 Nov 2008 18:55:26 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[ADMET Studies]]></category>
		<category><![CDATA[Collaborations]]></category>
		<category><![CDATA[Compound Libraries]]></category>
		<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[Drug-Like Compounds]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2008/11/11/wuxi-pharmatech-inks-new-three-year-deal-with-pfizer/</guid>
		<description><![CDATA[WuXi PharmaTech (NYSE: WX) has signed a new three-year CRO deal with Pfizer (NYSE: PFE) to collaborate on in vitro ADME (Absorption, Distribution, Metabolism and Excretion) services. Although WuXi has already been providing the services to Pfizer, WuXi said the new agreement â€œstrengthens an already productive relationship.â€ WuXi also provides Pfizer with synthetic chemistry, parallel [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2008/11/11/wuxi-pharmatech-inks-new-three-year-deal-with-pfizer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

